Technology
Health
Pharmaceutical

Kala Pharmaceuticals

$7.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.51 (-6.20%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell KALA and other stocks, options, ETFs, and crypto commission-free!

About

Kala Pharmaceuticals, Inc. Common Stock, also called Kala Pharmaceuticals, is a biopharmaceutical company, focused on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. Read More The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Waltham, MA.

Employees
130
Headquarters
Waltham, Massachusetts
Founded
2009
Market Cap
278.35M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
238.66K
High Today
$8.32
Low Today
$7.67
Open Price
$8.16
Volume
114.86K
52 Week High
$18.07
52 Week Low
$4.03

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Therapy
2017 IPO
US
North America

News

Simply Wall StMar 15

When Will Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Turn A Profit?

Kala Pharmaceuticals, Inc.’s (NASDAQ:KALA): Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. On 31 December 2018, the US$285m market-cap posted a loss of -US$66.7m for its most recent financial year. The most pressing concern for investors is KALA’s path to profitability – when will it breakeven? In this article, I will...

80
Seeking AlphaMar 11

Kala Pharmaceuticals, Inc.'s (KALA) CEO Mark Iwicki on Q4 2018 Results - Earnings Call Transcript

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q4 2018 Earnings Conference Call March 11, 2019 4:30 PM ET Company Participants Mary Reumuth - CFO Mark Iwicki - Chairman, President, CEO Kim Brazzell - Chief Medical Officer Todd Bazemore - COO Hongming Chen - Chief Scientific Officer Conference Call Participants David Maris - Wells Fargo Liana Moussatos - Wedbush Securities Yi Chen - H.C. Wainwright Operator Good day, and welcome to Kala Pharmaceuticals Fourth Quarter 2018 Earnings Conference Call. At t...

44
Yahoo FinanceMar 11

Kala Pharma: 4Q Earnings Snapshot

WALTHAM, Mass. (AP) _ Kala Pharmaceuticals Inc. (KALA) on Monday reported a loss of $25.2 million in its fourth quarter. On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 76 cents. Losses, adjusted to extinguish debt, were 75 cents per share. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 52 cents per share. Kala Pharma shares have climbed 77 percent since the beginning of ...

3

Earnings

-$0.76
-$0.63
-$0.49
-$0.36
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
β€”
Actual
-$0.76 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.